Phoenix PharmaLabs, Inc.
525 West 465 North
9 articles with Phoenix PharmaLabs, Inc.
Funds to accelerate development of first non-addictive opioid
85% Surveyed Said First Priority Is to Fund Research into Non-Addictive Pain Killers
Phoenix PharmaLabs Announces Investment Offering to Support Additional Research of Non-Addictive Opioid
Phoenix PharmaLabs today announced the launch of an equity offering campaign on the Netcapital platform.
Phoenix PharmaLabs Awarded $2.7 Million Research Grant from DOD/USAMRAA for Further Development of Non-Addictive Opioid
Phoenix PharmaLabs has been awarded a $2.7 million grant from the Department of Defense/US Army Medical Research Acquisition Activity.
Phoenix PharmaLabs Awarded NIH/NIDA Grant to Study Non-Addictive Opioid PPL-103 for Potential use as Cocaine Addiction Therapy Drug
This research is supported under award number R41DA044894.
Phoenix PharmaLabs Co-Founder to speak at Upcoming College on Problems of Drug Dependence (CPDD) 80th Annual Meeting in San Diego
Lawrence Toll, Ph.D., expected to describe company’s novel opioid that shows no signs of addiction potential
Phoenix PharmaLabs, Inc. Releases New Data Confirming That Their Novel Opioid Shows No Signs Of Addiction Potential
Novel Painkiller With Little Or No Signs Of Addiction And Other Serious Opioid Side Effects Patented By Phoenix PharmaLabs, Inc.
Aoxing Pharmaceutical Company Inc. and Phoenix PharmaLabs, Inc. Announce Strategic Alliance to Co-Develop a Novel Class of Molecules in Pain and Drug Addiction Therapeutics